Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis c Clear all

Conditions: Chronic Hepatitis C, Oxidative Stress
Interventions: silymarin, green tea extract (EGCG); Drug · Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Renal Failure Chronic, Hepatitis C
Interventions: glecaprevir/pibrentasvir treatment; Drug
Lead sponsor: Raymond Chung; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more

Conditions: Opioid-Related Disorders, Hepatitis C (HCV), Human Immunodeficiency Virus (HIV), Drug Overdose, Substance Abuse, Intravenous Drug Usage, Opiate Substitution Treatment, Sexually Transmitted Diseases
Interventions: Health kiosk; Behavioral
Lead sponsor: April M Young; Other
Eligibility: 18 Years and older
Enrollment: 752 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hepatitis C
Interventions: Pioglitazone, Prednisone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hepatitis C, Chronic
Interventions: Autoinjector, Pre-filled syringe; Device
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 12
States / cities: Los Angeles, California • Bradenton, Florida • Orlando, Florida + 9 more

Conditions: Hepatitis C, Substance Use Disorders
Interventions: Virtual Care Coordination; Behavioral
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Hepatitis C, Liver Diseases
Interventions: Patient portal message; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 54 Years to 74 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hepatitis C, Chronic
Interventions: PEGylated recombinant interleukin 29 (PEG-rIL-29); Drug
Lead sponsor: ZymoGenetics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: Chicago, Illinois • Detroit, Michigan • Rochester, Minnesota + 6 more

Conditions: Chronic Hepatitis C Virus Infection
Interventions: PEGIntron plus ribavirin; Drug
Lead sponsor: Hepatitis Resource Network; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Hepatitis C
Interventions: VX-985 or matching placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Overland Park, Kansas • Baltimore, Maryland • Tacoma, Washington

Conditions: Thrombocytopenia, Hepatitis C
Interventions: Eltrombopag; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatitis C, Chronic
Interventions: PEG-rIL-29, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: ZymoGenetics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 29
States / cities: Beverly Hills, California • Coronado, California • La Jolla, California + 26 more

Conditions: Colorectal Cancer Screening, Hepatitis C Virus
Interventions: MATCHES; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 45 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hepatitis C, Chronic, Cirrhosis
Interventions: Telaprevir, Boceprevir, Peg-IFN, Ribavirin; Drug
Lead sponsor: Louis Stokes VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers, Hepatobiliary Cancers Liver
Interventions: Not listed
Lead sponsor: Samuel So; Other
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Liver Transplant, Hepatitis C
Interventions: sofosbuvir/velpatasvir; Drug
Lead sponsor: Fernanda P Silveira, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Hepatitis C, Chronic Hepatitis B
Interventions: 4-Methylumbelliferone (Heparvit®); Drug
Lead sponsor: MTmedical Institute of Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: PTSD
Interventions: Glecaprevir/pibrentasvir, Placebo; Drug · Other
Lead sponsor: White River Junction Veterans Affairs Medical Center; Federal
Eligibility: 19 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: White River Junction, Vermont

Conditions: HEPATITIS C (HCV), Incarceration, Injection Drug Use, Implementation Science
Interventions: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker; Drug · Other
Lead sponsor: Lifespan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cranston, Rhode Island

Conditions: Opioid Use Disorder, Infectious Disease, Risk Reduction Behavior, Substance Use, Substance Abuse, Stimulant Use Disorder
Interventions: Patient Navigator, Mobile Health Unit; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: New Haven, Connecticut • Dallas, Texas • Fort Worth, Texas

Conditions: Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions: Esophageal cooling/warming device, Mild hypothermia, Normothermia; Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Aurora, Colorado • Houston, Texas

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 12
States / cities: Anaheim, California • San Diego, California • San Francisco, California + 8 more

Conditions: HIV-1 and Hepatitis C Co-Infection
Interventions: pioglitazone, peginterferon, ribavirin; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Newark, New Jersey + 4 more

Conditions: Hepatitis C, HIV Infections
Interventions: Peginterferon alfa-2b, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk

Study the Relationship Between Obesity and Hepatitis C Replication

A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C

Eliminating HCV in Rural South Carolina Utilizing NP Led Mobile Clinics and Virtual Care Coordination

Electronic Record Assimilation and Subsequent Eradication of Hepatitis C

Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection

PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

Study of VX-985 in Subjects With Chronic Hepatitis C

Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Genetic Analysis of Liver Cancer

The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients

4-Methylumbelliferone as a Treatment for Chronic HBV/HCV

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

Implementing Low-Barrier HCV Treatment in a Jail Setting

Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients